Shots:

• The P- IIb/III ALLEGRO trial evaluates ritlecitinib {50/30mg- (with/out one month of initial treatment with ritlecitinib- 200 mg)- 10mg- PO- qd} vs PBO in 718 patients aged ≥12yrs. with alopecia areata
• The trial met its 1EPs of improving scalp hair regrowth- patients with 30/50mg dose had ≤ 20% scalp hair loss @24wks.- the safety profile of the therapy was consistent with previous studies
• Ritlecitinib is a JAK3/TEC inhibitor & is currently being evaluated for vitiligo- RA- CD- and UC. The therapy has received BTD from the FDA to treat alopecia areata on Sept’2018

  | Ref: Pfizer | Image: The Wall Street Journal